Clinical Trials
Clinical Trial Detail
Return to search results.
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (RELEVANCE)
Complete title: A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus chemotherapy Followed by Rituximab in subjects with Previously Untreated Follicular Lymphoma (The RELEVANCE Trial)
| Research Study Number | 7636 | ||
| Principal Investigator | Edward Libby | ||
| Phase | III |
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
- Genders Eligible for Study: Both
- Histologically confirmed follicular lymphoma grade 1, 2 or 3a, Stage II-IV
- Have no prior systemic treatment for lymphoma
- Symptomatic follicular lymphoma requiring treatment.
- Age =18 years
- Eastern Cooperative oncology group performance status 0-2
- Willing to follow pregnancy precautions
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
- Major surgery (excluding lymph node biopsy) within 28 days prior to signing informed consent.
- Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)
- Known sensitivity or allergy to murine products.
- Presence or history of central nervous system involvement by lymphoma
- At high risk for a venous thromboembolic event (VTE) and not willing to take VTE prophylaxis
- Any of the following laboratory abnormalities:
- serum aspartate transaminase or alanine transaminase > 3x upper limit of normal (ULN), except in patients with documented liver involvement by lymphoma
- total bilirubin > 2.0 mg/dl (34 µmol/L) except in cases of Gilberts Syndrome and documented liver or pancreatic involvement by lymphoma
- creatinine clearance of < 30 mL/min
Other exclusion criteria may apply.
|
Keywords
Hematologic Malignancies; Lymphoma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
- Diseases
& Research
- Treatment
& Support
- About Us
- Labs &
Projects
- Events &
Community Programs
- How You
Can Help Us
The Hutchinson Center's world-renowned scientists are discovering new ways to detect, prevent and treat cancer, HIV/AIDS and many other diseases.
- License Our Discoveries
The Hutchinson Center's world-renowned researchers work together to pursue lifesaving therapies that will help eliminate cancer and related diseases.
The Hutchinson Center's clinical research breakthroughs are delivered to patients through our treatment arm, the Seattle Cancer Care Alliance. This collaboration combines the strengths of the Hutchinson Center, UW Medicine and Seattle Children's.
You can help eliminate cancer and related diseases by attending Hutchinson Center events and participating in our other fundraising and community efforts.
- Divisions
The Hutchinson Center's pioneering researchers push the boundaries of science to find new ways to prevent, detect and treat cancer and related diseases.
Private support is critical to fund new research ideas and innovations, accelerating our ability to make lifesaving discoveries.
